In virtually every country in the world, women live longer than men. In France, the gap is around six years. In Japan, it exceeds seven. In some parts of the world, it reaches ten.
For a long time, this gap was attributed to behavioural factors: men smoke more, take more risks, see doctors less often. These explanations are partly correct. But they are insufficient.
Contemporary geroscience has amassed a body of data pointing to a more fundamental reality: men and women age differently at the cellular and molecular level. The differences run through the epigenome, mitochondrial metabolism, immunology, hormonal regulation and the oxidative-stress response.
The longevity gap: beyond behaviour
Studies of cloistered religious populations — monks and nuns living in comparable environments — show that the longevity gap persists, narrowed but not erased. Studies of centenarian populations reveal a striking asymmetry: women make up roughly 80% of centenarians in most developed countries. Among supercentenarians (110+), the proportion exceeds 90%.
This data suggests that exceptional longevity is biologically skewed toward women — a skew that behavioural differences alone cannot fully explain.
Sex chromosomes: a fundamental biological asymmetry
Women have two X chromosomes (XX); men have one X and one Y (XY). In women, if a gene on the first X chromosome is mutated, its counterpart on the second X chromosome can compensate — a redundancy that doesn't exist in men. Many genes involved in DNA repair, immune response and cellular metabolism are located on the X chromosome: women benefit from a "genetic insurance policy" that men lack.
Research by Lars Forsberg in Sweden has also shown that somatic loss of the Y chromosome in blood cells — a phenomenon that increases with age in men — is associated with reduced life expectancy and a higher risk of cardiovascular disease and cancer. This loss is now considered a biomarker of male aging.
Mitochondria: a maternal link to longevity
Mitochondrial DNA is transmitted exclusively through the maternal line. Several researchers have developed the "mother's curse" hypothesis: mitochondrial DNA mutations that are harmful to males but neutral to females can accumulate in the population without being eliminated by natural selection.
Female mitochondria also show different bioenergetic properties. Estrogens, notably estradiol, stimulate mitochondrial biogenesis via PGC-1α, improve respiratory-chain efficiency, and reduce ROS production — effects that contribute to a less oxidative cellular environment in women of reproductive age.
The immune system: a double-edged female advantage
Women mount more robust immune responses to infections and vaccinations. They produce more antibodies, have more active cytotoxic T cells, and show a more reactive innate immunity. But this advantage comes at a cost: more than 80% of patients with lupus, rheumatoid arthritis, multiple sclerosis or Hashimoto's thyroiditis are women. Immune-system aging (immunosenescence) takes different forms by sex, with distinct consequences for inflammaging and resistance to chronic disease.
Biological sex is not a confounding variable geroscience seeks to neutralise. It is a central explanatory variable, indispensable to any precision intervention on aging.
Menopause, andropause and accelerated aging
Menopause marks the end of ovarian estradiol and progesterone production. Estradiol has pleiotropic effects: cardiovascular protection, neuroprotective effects, stimulation of mitochondrial biogenesis, and modulation of epigenetic profiles. Its sharp drop at menopause destabilises all of these systems simultaneously. Several studies using the Horvath and GrimAge clocks have shown that menopause is associated with an acceleration of epigenetic age — menopausal women show a statistically more advanced biological age than premenopausal women of the same chronological age.
The decline in NAD+ is also accelerated by menopause: estradiol stimulates the expression of NAMPT, the rate-limiting enzyme in its biosynthesis. Its drop contributes to the NAD+ depletion that characterises post-menopausal female aging. In men, the decline in testosterone is instead gradual and begins as early as one's thirties — roughly 1% a year — contributing to male sarcopenia, increased visceral fat, and a progressive deterioration of the metabolic profile.
Sex differences in longevity signalling pathways
The IGF-1/insulin pathway shows significant sex differences documented in human centenarians. AMPK and mTOR respond differently depending on hormonal sex — partly under the influence of estrogens and testosterone — with consequences for the regulation of autophagy, mitochondrial biogenesis and protein synthesis. The sirtuins also show sex-based differences in expression and activity, with SIRT1 modulated by estrogens in several tissues.
Implications for sex-specific precision cellular nutrition
Biological sex is a scientifically unavoidable variable in any approach to longevity-oriented cellular nutrition. NAD+ precursor needs are not identical before and after menopause. Oxidative pressures on mitochondria differ between a 45-year-old man and a perimenopausal 45-year-old woman. This isn't a matter of gendered marketing. It's a matter of biology — the same biology that justifies the existence of two distinct formulas, Her and Him, within Cellular Daily.
In conclusion
The longevity gap between men and women is the documented result of deep biological differences — chromosomal, mitochondrial, immune, epigenetic and hormonal — operating at the cellular level throughout life.
Contemporary geroscience no longer treats biological sex as a confounding variable. It treats it as a central explanatory variable — one whose understanding is essential to any precision intervention on aging.
This article is published for informational and educational purposes. It does not constitute medical advice and does not replace consultation with a healthcare professional.
